Traders sold shares of Zoetis Inc. (NYSE:ZTS) on strength during trading hours on Wednesday. $30.72 million flowed into the stock on the tick-up and $70.26 million flowed out of the stock on the tick-down, for a money net flow of $39.54 million out of the stock. Of all companies tracked, Zoetis had the 10th highest net out-flow for the day. Zoetis traded up $0.88 for the day and closed at $51.81

ZTS has been the topic of a number of research reports. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $53.00 price target on the stock in a research note on Monday, May 9th. Jefferies Group restated a “buy” rating on shares of Zoetis in a research note on Sunday, May 8th. Stifel Nicolaus initiated coverage on Zoetis in a research note on Tuesday, May 31st. They issued a “buy” rating and a $58.00 price target on the stock. Credit Suisse Group AG restated a “buy” rating on shares of Zoetis in a research note on Sunday, May 22nd. Finally, Guggenheim restated a “buy” rating and issued a $60.00 price target on shares of Zoetis in a research note on Monday, July 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zoetis currently has an average rating of “Buy” and a consensus target price of $54.63.

The stock has a market cap of $25.65 billion and a PE ratio of 40.35. The stock has a 50 day moving average of $49.17 and a 200 day moving average of $45.87.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. During the same period last year, the firm earned $0.43 earnings per share. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Zoetis’s quarterly revenue was up 2.8% compared to the same quarter last year. Equities analysts anticipate that Zoetis Inc. will post $1.90 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 30th. Stockholders of record on Thursday, June 30th will be issued a dividend of $0.095 per share. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date of this dividend is Tuesday, June 28th.

Several large investors recently made changes to their positions in the stock. Advantus Capital Management Inc raised its stake in shares of Zoetis by 2.6% in the fourth quarter. Advantus Capital Management Inc now owns 44,257 shares of the company’s stock worth $2,121,000 after buying an additional 1,110 shares during the period. Pittenger & Anderson Inc. raised its stake in Zoetis by 5.1% in the fourth quarter. Pittenger & Anderson Inc. now owns 53,605 shares of the company’s stock valued at $2,569,000 after buying an additional 2,600 shares during the last quarter. Calvert Investment Management Inc. raised its stake in Zoetis by 24.8% in the fourth quarter. Calvert Investment Management Inc. now owns 28,411 shares of the company’s stock valued at $1,361,000 after buying an additional 5,639 shares during the last quarter. American International Group Inc. raised its stake in Zoetis by 3.5% in the fourth quarter. American International Group Inc. now owns 205,930 shares of the company’s stock valued at $9,868,000 after buying an additional 7,038 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. raised its stake in Zoetis by 21.0% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 124,137 shares of the company’s stock valued at $5,949,000 after buying an additional 21,562 shares during the last quarter.

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.